SGEN
$SGEN
Seagen Inc.
Antibody-drug conjugate biotech company advancing targeted cancer therapies.
HealthcareAnalyst Rating
Hold
9 Buy / 14 Hold / 0 Sell
Subscribers
0
Tracking this ticker
Next Report
Sun, Mar 22
Weekly updates
Latest Report
SGEN: Seagen outlook — ADC leadership vs. profitability
Seagen ($SGEN) sits at a crossroads, with a $229 mean analyst target reflecting confidence in its ADC and targeted oncology portfolio, while negative TTM EPS highlights near-term profitability pressures.
Mar 16, 2026